HIV

No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
Thu, 02/8/18 - 11:18 am
GSK
R&D
Pharma CEOs
Emma Walmsley
Advair
Novartis
Sandoz
Gilead Sciences
HIV
A new pill to treat HIV just got approved — and it could shake up a $22 billion market
Business Insider
Thu, 02/8/18 - 09:30 am
HIV
Gilead Sciences
FDA
Bictegravir/emtricitabine/tenofovir alafenamide
Ready to take on Glaxo, Gilead's combo HIV med Biktarvy wins $6B FDA nod
Fierce Pharma
Wed, 02/7/18 - 10:32 pm
GSK
Gilead Sciences
HIV
FDA
Biktarvy
Aetna to pay $17 million over mailing that revealed HIV meds
Stat
Wed, 01/17/18 - 09:50 pm
Aetna
HIV
patients
privacy
5 Ways Gilead Sciences Plans to Return to Growth
Motley Fool
Tue, 01/9/18 - 10:55 pm
Gilead Sciences
HIV
liver disease
cell therapy
inflammation
M&A
Teva rolls out exclusive generic of Gilead's Viread at the end of an awful week
Fierce Pharma
Fri, 12/15/17 - 11:40 pm
Teva Pharmaceutical
Gilead Sciences
Viread
hepatitis B
HIV
antivirals
Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches
Investors Business Daily
Thu, 12/7/17 - 09:16 am
Gilead Sciences
drug launches
HIV
bictegravir
J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine
Endpoints
Thu, 11/30/17 - 09:46 am
JNJ
HIV
vaccines
R&D
mosaic vaccine
Imbokodo
HVTN 705/HPX2008
Fresh off its Juluca approval, GlaxoSmithKline beefs up trials of long-acting HIV duo
Fierce Pharma
Tue, 11/28/17 - 09:05 pm
GSK
cabotegravir
HIV
Endurant
ViiV
JNJ
Janssen
J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space
Yahoo/Zacks.com
Sat, 11/25/17 - 12:39 pm
JNJ
GSK
Jucala
HIV
With billions riding on their success, GSK bags quick OK for its two-drug HIV combo Juluca
Endpoints
Tue, 11/21/17 - 10:47 pm
GSK
HIV
Juluca
ViiV
GSK and Gilead go head to head as HIV drugs enter new phase
Reuters
Fri, 11/3/17 - 11:01 am
GSK
Gilead Sciences
HIV
Dolutegravir
bictegravir
With solid results in hand, Gilead inks manufacturing deal for HIV med
Biopharma Dive
Thu, 10/5/17 - 10:19 am
Gilead Sciences
HIV
drug manufacturing
FTC/TAF
J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK
Endpoints
Mon, 09/25/17 - 09:44 am
JNJ
HIV
Gilead
GSK
FDA
D/C/F/TAF
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Motley Fool
Thu, 09/7/17 - 09:40 am
Gilead Sciences
Kite Pharma
HIV
hepatitis C
M&A
AIDS activists urge N.Y. attorney general to probe Gilead for antitrust violations
Stat
Tue, 08/29/17 - 09:15 pm
Gilead Sciences
Truvada
antitrust
AIDS
HIV
Gilead circles February 12 on its calendar as D-day for its HIV franchise
Endpoints
Fri, 08/11/17 - 10:56 am
Gilead Sciences
HIV
FTC/TAF
FDA
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff
Fierce Pharma
Wed, 08/9/17 - 11:20 am
Bristol-Myers Squibb
HIV
layoffs
patent cliff
Reyataz
Sustiva
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
Motley Fool
Mon, 07/31/17 - 09:59 pm
Gilead Sciences
earnings
hepatitis C
HIV
M&A
J&J reports positive results for HIV regimen
BioPharma Dive
Wed, 07/26/17 - 11:21 am
JNJ
HIV
Gilead Sciences
Darunavir

Pages